Evidence map›Paper›PMID 41557789›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2026

Functionally heterogeneous intratumoral CD4

Tony Li, Arielle Ilano, Marcel Arias-Badia, Diamond Luong, Hewitt Chang, Serena S Kwek, Kathryn Allaire, Arun Chumber, Mason Sakamoto, Matthew Clark and 9 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. The role of CD8Frontiers in immunology · 2026
    Pooled it
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors.

Tony Li *Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, CA 94143.ORCID 0000-0003-3546-123X
Arielle Ilano *Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, CA 94143.ORCID 0000-0002-0979-7445
Marcel Arias-Badia *Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, CA 94143.ORCID 0000-0003-2270-0676
Diamond LuongDivision of Hematology/Oncology, Department of Medicine, University of California, San Francisco, CA 94143.ORCID 0000-0001-6832-5408
Hewitt ChangDivision of Hematology/Oncology, Department of Medicine, University of California, San Francisco, CA 94143.
Serena S KwekDivision of Hematology/Oncology, Department of Medicine, University of California, San Francisco, CA 94143.
Kathryn AllaireDivision of Hematology/Oncology, Department of Medicine, University of California, San Francisco, CA 94143.
Arun ChumberDivision of Hematology/Oncology, Department of Medicine, University of California, San Francisco, CA 94143.ORCID 0009-0004-8247-437X
Mason SakamotoDivision of Hematology/Oncology, Department of Medicine, University of California, San Francisco, CA 94143.
Matthew ClarkDivision of Hematology/Oncology, Department of Medicine, University of California, San Francisco, CA 94143.
Averey LeaDivision of Hematology/Oncology, Department of Medicine, University of California, San Francisco, CA 94143.
Mark BridgeHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94143.ORCID 0000-0002-2997-981X
Brandon ChenDivision of Hematology/Oncology, Department of Medicine, University of California, San Francisco, CA 94143.
Eric LiuDivision of Hematology/Oncology, Department of Medicine, University of California, San Francisco, CA 94143.ORCID 0000-0003-2286-0856
Sima PortenDepartment of Urology, University of California, San Francisco, CA 94143.
Maxwell V MengDepartment of Urology, University of California, San Francisco, CA 94143.
Lauren I R ErlichDepartment of Molecular Biosciences, The University of Texas, Austin, TX 78712.ORCID 0000-0002-1697-1755
David Y OhDivision of Hematology/Oncology, Department of Medicine, University of California, San Francisco, CA 94143.
Lawrence FongDivision of Hematology/Oncology, Department of Medicine, University of California, San Francisco, CA 94143.ORCID 0000-0002-6428-428X

Funding

UCSF Specialized Programs of Research Excellence (SPOREs) in Prostate CancerP50CA275741 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ERIC J SMALL · 2024 to 2026
$8.8M
Determinants of response to cancer immunotherapyR35CA253175 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Lawrence Fong · 2021 to 2026
$5.8M
HHS | NIH | National Cancer Institute (NCI) 1R35CA253175HHS | NIH | National Cancer Institute (NCI) P50CA275741NCI NIH HHS P50 CA275741NCI NIH HHS R35 CA253175
6 · The paper itself

Abstract

Conventional single-positive (SP) CD4

Indexed as

Carcinoma, Renal CellCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesKidney NeoplasmsHumansTumor MicroenvironmentimmunotherapyT cellstumor immunity

Identifiers

PMID41557789
PMCPMC12849695

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.